Exact Mass: 499.9681

Exact Mass Matches: 499.9681

Found 56 metabolites which its exact mass value is equals to given mass value 499.9681, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Perfluorooctanesulfonate (PFOS)

1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid

C8HF17O3S (499.9375)


Perfluorooctane-1-sulfonic acid is a perfluoroalkanesulfonic acid that is octane-1-sulfonic acid in which all seventeen of the hydrogens that are attached to carbons hvae been replaced by fluorines. It has a role as an antilipemic drug and a persistent organic pollutant. It is functionally related to an octane-1-sulfonic acid. Perfluorooctane sulfonate (PFOS) can cause cancer according to an independent committee of scientific and health experts. It can cause developmental toxicity according to The Environmental Protection Agency (EPA). Perfluorooctanesulfonic acid or perfluorooctane sulfonate (PFOS), is a man-made fluorosurfactant and global pollutant. PFOS was the key ingredient in Scotchgard, a fabric protector made by 3M, and numerous stain repellents. It was added to Annex B of the Stockholm Convention on Persistent Organic Pollutants in May 2009. PFOS can form from the degradation of precursors in addition to industrial production. The PFOS levels that have been detected in wildlife are considered high enough to affect health parameters, and recently higher serum levels of PFOS were found to be associated with increased risk of chronic kidney disease in the general US population, consistent with earlier animal studies. This association was independent of confounders such as age, sex, race/ethnicity, body mass index, diabetes, hypertension, and serum cholesterol level.

   

myo-Inositol 1,3,4,5-tetrakisphosphate

{[(1S,2S,3S,4S,5R,6S)-2,4-dihydroxy-3,5,6-tris(phosphonooxy)cyclohexyl]oxy}phosphonic acid

C6H16O18P4 (499.9287)


myo-Inositol 1,3,4,5-tetrakisphosphate (CAS: 102850-29-3), also known as IP4, is a second messenger responsible for mediating Ca2+ entry through the plasma membrane and mobilizing intracellular Ca2+ by acting synergistically with inositol 1,4,5-trisphosphate (IP3). Inositol 1,4,5-trisphosphate 3-kinase (IP3K, EC 2.7.1.127) phosphorylates IP3 into IP4. Evidence shows that IP4 can activate a protein with ras- and rap-GAP activity and finally inactivate the G protein. This indicates that IP4 regulates Ca2+ influx in a GTP-dependent way, which potentially links the IP3 signalling pathway to GTP-regulated signalling mechanisms. IP4 is demonstrated to be a common regulator in Ca2+ homeostasis. IP4 can bind with a high affinity to several intracellular proteins: synaptotagmin (I and II), Gap1, Btk, and centaurin-alpha and may interact with synaptotagmin to inhibit synaptic transmission. IP4 also acts as a mediator in neuronal death in the ischemic hippocampus. IP4 production is not always associated with a modification in calcium concentration, and control of calcium mobilization is not the sole function proposed for IP4. IP4 defines an essential signalling pathway for T cell precursor responsiveness and development. In the thymus, IP4 is essential during the positive and negative selection of double-positive thymocytes, and in the control of thymocyte reactivity to antigens. IP4 is also a substrate for type I inositol-1,4,5-trisphosphate 5-phosphatase, phosphatidylinositol 4,5-bisphosphate 5-phosphatase A, and skeletal muscle and kidney enriched inositol phosphatase (PMID: 15740635, 14517551).

   

D-myo-Inositol 1,3,4,6-tetrakisphosphate

{[(1R,2s,3S,4S,5r,6R)-2,5-dihydroxy-3,4,6-tris(phosphonooxy)cyclohexyl]oxy}phosphonic acid

C6H16O18P4 (499.9287)


D-myo-Inositol 1,3,4,6-tetrakisphosphate, also known as Ins(1,3,4,6)P4, belongs to the class of organic compounds known as inositol phosphates. Inositol phosphates are compounds containing a phosphate group attached to an inositol (or cyclohexanehexol) moiety. D-myo-Inositol 1,3,4,6-tetrakisphosphate is an extremely strong acidic compound (based on its pKa). D-myo-Inositol 1,3,4,6-tetrakisphosphate participates in a number of enzymatic reactions. In particular, D-myo-inositol 1,3,4,6-tetrakisphosphate can be converted into D-myo-inositol 1,3,4,5,6-pentakisphosphate through the action of the enzyme inositol polyphosphate multikinase. In addition, D-myo-inositol 1,3,4,6-tetrakisphosphate can be biosynthesized from inositol 1,3,4-trisphosphate; which is mediated by the enzyme inositol-tetrakisphosphate 1-kinase. In humans, D-myo-inositol 1,3,4,6-tetrakisphosphate is involved in inositol phosphate metabolism and is a substrate for the tyrosine-protein kinase BTK. 1D-Myo-inositol 1,3,4,6-tetrakisphosphate is a substrate for Tyrosine-protein kinase BTK and Inositol polyphosphate multikinase. [HMDB]

   

D-myo-Inositol 3,4,5,6-tetrakisphosphate

{[(1R,2S,3R,4S,5S,6R)-3,4-dihydroxy-2,5,6-tris(phosphonooxy)cyclohexyl]oxy}phosphonic acid

C6H16O18P4 (499.9287)


Inositol phosphates are a family of water-soluble intracellular signalling molecules derived from membrane inositol phospholipids. They undergo a variety of complex interconversion pathways, and their levels are dynamically regulated within the cytosol in response to a variety of agonists. D-myo-Inositol 3,4,5,6-tetrakisphosphate, also known as Ins(3,4,5,6)P4, has a direct biphasic (activation/inhibition) effect on an epithelial Ca2+-activated chloride channel. The effect of Ins(3,4,5,6)P4 is not mimicked by other inositol tetrakisphosphate isomers, is dependent on the prevailing calcium concentration, and is influenced when channels are phosphorylated by calmodulin kinase II. The predominant effect of Ins(3,4,5,6)P4 on phosphorylated channels is inhibitory at levels of intracellular calcium observed in stimulated cells. Ins(3,4,5,6)P4 activity acts to inhibit calcium-dependent chloride secretion. The secretion of fluid and electrolytes across intestinal epithelial cells in response to Ca2+-dependent secretagogues is a tightly regulated process that is subject to both positive and negative influences. Agonists of Gq protein-coupled receptor (GqPCRs) appear to have the ability to evoke antisecretory mechanisms. One is mediated by the generation of Ins(3,4,5,6)P4 and serves to chronically downregulate epithelial responsiveness to subsequent challenges with Ca2+-dependent agonists (PMID: 12388102, 11408264). Inositol phosphates are a family of water-soluble intracellular signaling molecules derived from membrane inositol phospholipids. They undergo a variety of complex interconversion pathways, and their levels are dynamically regulated within the cytosol in response to a variety of agonists. D-Myo-inositol (3,4,5,6) tetrakisphosphate (Ins(3,4,5,6)P4) has a direct biphasic (activation/inhibition) effect on an epithelial Ca2+-activated chloride channel. The effect of Ins(3,4,5,6)P4 is not mimicked by other inositol tetrakisphosphate isomers, is dependent on the prevailing calcium concentration, and is influenced when channels are phosphorylated by calmodulin kinase II. The predominant effect of Ins(3,4,5,6)P4 on phosphorylated channels is inhibitory at levels of intracellular calcium observed in stimulated cells. Ins(3,4,5,6)P4 activity acts to inhibit calcium-dependent chloride secretion. The secretion of fluid and electrolytes across intestinal epithelial cells in response to Ca2+-dependent secretagogues is a tightly regulated process that is subject to both positive and negative influences. Agonists of Gq protein-coupled receptor (GqPCRs) appear to have the ability to evoke antisecretory mechanisms. One is mediated by the generation of Ins(3,4,5,6)P4 and serves to chronically downregulate epithelial responsiveness to subsequent challenge with Ca2+-dependent agonists. (PMID: 12388102, 11408264) [HMDB]

   

D-myo-Inositol 1,4,5,6-tetrakisphosphate

{[(1S,2R,3S,4R,5R,6S)-3,4-dihydroxy-2,5,6-tris(phosphonooxy)cyclohexyl]oxy}phosphonic acid

C6H16O18P4 (499.9287)


Inositol phosphates are a family of water-soluble intracellular signalling molecules derived from membrane inositol phospholipids. They undergo a variety of complex interconversion pathways, and their levels are dynamically regulated within the cytosol in response to a variety of agonists. Their biological actions can be quite specific to particular inositol phosphates. D-myo-Inositol 3,4,5,6-tetrakisphosphate, also known as Ins(1,4,5,6)P4 is phosphorylated by inositolphosphate-multikinase (IMPK). Ins(1,4,5,6)P4 has been shown to regulate Cl- transport, to be a phosphoinositide 3-kinase antagonist, and to bind tightly to some pleckstrin homology domains. It may also contribute to transcriptional regulation (PMID: 16376887, 10720331, 8809047, 9405634). 1D-Myo-inositol 1,4,5,6-tetrakisphosphate has been shown to regulate Cl- transport, to be a phosphoinositide 3-kinase antagonist, and to bind tightly to some pleckstrin homology domains, and finally, it may contribute to transcriptional regulation. Inositol phosphates comprise a large family of intracellular signals which play many important roles in cell biology. These biological actions can be quite specific to one particular inositol phosphate. 1D-myo-Inositol 1,4,5,6-tetrakisphosphate (Ins(1,4,5,6)P4) is phosphorylated by inositolphosphate-multikinase (IPMK; this enzyme has the capacity to regulate the cellular levels of Ins(1,4,5,6)P4 in mammalian cells. (PMID: 16376887, 10720331, 8809047, 9405634) [HMDB]

   

Myo-inositol,1,3,4,5-tetrakis(dihydrogen phosphate)

{[2,6-dihydroxy-3,4,5-tris(phosphonooxy)cyclohexyl]oxy}phosphonic acid

C6H16O18P4 (499.9287)


   

Perfluoro tert-butylcyclohexane

1,1,2,2,3,3,4,4,5,5,6-undecafluoro-6-[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]cyclohexane

C10F20 (499.9681)


   

isoPFOS

isoPFOS

C8HF17O3S (499.9375)


Disclaimer: While authors make an effort to ensure that the content of this record is accurate, the authors make no representations or warranties in relation to the accuracy or completeness of the record. This record do not reflect any viewpoints of the affiliation and organization to which the authors belong.

   

5mPFOS

5mPFOS

C8HF17O3S (499.9375)


Disclaimer: While authors make an effort to ensure that the content of this record is accurate, the authors make no representations or warranties in relation to the accuracy or completeness of the record. This record do not reflect any viewpoints of the affiliation and organization to which the authors belong.

   

4mPFOS

4mPFOS

C8HF17O3S (499.9375)


Disclaimer: While authors make an effort to ensure that the content of this record is accurate, the authors make no representations or warranties in relation to the accuracy or completeness of the record. This record do not reflect any viewpoints of the affiliation and organization to which the authors belong.

   

3mPFOS

3mPFOS

C8HF17O3S (499.9375)


Disclaimer: While authors make an effort to ensure that the content of this record is accurate, the authors make no representations or warranties in relation to the accuracy or completeness of the record. This record do not reflect any viewpoints of the affiliation and organization to which the authors belong.

   

2mPFOS

2mPFOS

C8HF17O3S (499.9375)


Disclaimer: While authors make an effort to ensure that the content of this record is accurate, the authors make no representations or warranties in relation to the accuracy or completeness of the record. This record do not reflect any viewpoints of the affiliation and organization to which the authors belong.

   

1mPFOS

1mPFOS

C8HF17O3S (499.9375)


Disclaimer: While authors make an effort to ensure that the content of this record is accurate, the authors make no representations or warranties in relation to the accuracy or completeness of the record. This record do not reflect any viewpoints of the affiliation and organization to which the authors belong.

   
   

nPFOS

nPFOS

C8HF17O3S (499.9375)


Disclaimer: While authors make an effort to ensure that the content of this record is accurate, the authors make no representations or warranties in relation to the accuracy or completeness of the record. This record do not reflect any viewpoints of the affiliation and organization to which the authors belong.

   

44m2PFOS

44m2PFOS

C8HF17O3S (499.9375)


Disclaimer: While authors make an effort to ensure that the content of this record is accurate, the authors make no representations or warranties in relation to the accuracy or completeness of the record. This record do not reflect any viewpoints of the affiliation and organization to which the authors belong.

   

Perfluorooctanesulfonic acid

1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonic acid

C8HF17O3S (499.9375)


Perfluorooctanesulfonic acid or perfluorooctane sulfonate (PFOS), is a man-made fluorosurfactant and global pollutant. PFOS was the key ingredient in Scotchgard, a fabric protector made by 3M, and numerous stain repellents. It was added to Annex B of the Stockholm Convention on Persistent Organic Pollutants in May 2009. PFOS can form from the degradation of precursors in addition to industrial production. The PFOS levels that have been detected in wildlife are considered high enough to affect health parameters, and recently higher serum levels of PFOS were found to be associated with increased risk of chronic kidney disease in the general US population, consistent with earlier animal studies. This association was independent of confounders such as age, sex, race/ethnicity, body mass index, diabetes, hypertension, and serum cholesterol level. Perfluorooctanesulfonic acid. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=1763-23-1 (retrieved 2024-09-27) (CAS RN: 1763-23-1). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

   

Perfluorooctylsulfonic acid

Perfluorooctylsulfonic acid

C8HF17O3S (499.9375)


   

D-myo-Inositol-1,2,5,6-tetraphosphate

D-myo-inositol-1,2,5,6-tetra(dihydrogen phosphate), tetrasodium salt

C6H16O18P4 (499.9287)


   

D-myo-Inositol-1,2,3,4-tetraphosphate

D-myo-Inositol-1,2,3,4-tetrakis(dihydrogen phosphate), tetrasodium salt

C6H16O18P4 (499.9287)


   

D-myo-Inositol-1,2,3,5-tetraphosphate

D-myo-Insitol-1,2,3,5-tetrakis(dihydrogen phosphate), tetrasodium salt

C6H16O18P4 (499.9287)


   

D-myo-Inositol-1,2,3,6-tetraphosphate

D-myo-Inositol-1,2,3,6-tetrakis (dihydrogen phosphate), tetrasodium salt

C6H16O18P4 (499.9287)


   

D-myo-Inositol-1,2,4,5-tetraphosphate

D-myo-Inositol-1,2,4,5-tetrakis(dihydrogen phosphate), tetrasodium salt

C6H16O18P4 (499.9287)


   

D-myo-Inositol-3,4,5,6-tetraphosphate

D-myo-inositol-3,4,5,6-tetra(hydrogen phosphate)

C6H16O18P4 (499.9287)


   

D-myo-Inositol-2,3,5,6-tetraphosphate

D-myo-inositol-2,3,5,6-tetrakis (dihydrogen phosphate), tetrasodium salt

C6H16O18P4 (499.9287)


   

D-myo-Inositol-2,3,4,5-tetraphosphate

D-myo-inositol-2,3,4,5-tetrakis(dihydrogen phosphate), octaammonium salt

C6H16O18P4 (499.9287)


   

8-SULFANYL-5-QUINOLINESULFONIC ACID HEMIHYDRATE

8-SULFANYL-5-QUINOLINESULFONIC ACID HEMIHYDRATE

C18H16N2O7S4 (499.984)


   

1H,1H-Perfluorodecan-1-ol

1H,1H-Perfluorodecan-1-ol

C10H3F19O (499.988)


   

Iron(3+) tris(diethylcarbamodithioate)

Iron(3+) tris(diethylcarbamodithioate)

C15H30FeN3S6 (500.0113)


   

2-(5-BROMO-2-PYRIDYLAZO)-5-[N-PROPYL-N-(3-SULFOPROPYL)AMINO]PHENOL DISODIUM SALT DIHYDRATE

2-(5-BROMO-2-PYRIDYLAZO)-5-[N-PROPYL-N-(3-SULFOPROPYL)AMINO]PHENOL DISODIUM SALT DIHYDRATE

C17H19BrN4Na2O4S (500.0106)


   

2,2,3,4,4,5,5,6,6,7,8,8,8-tridecafluoro-3,7-bis(trifluoromethyl)octan-1-ol

2,2,3,4,4,5,5,6,6,7,8,8,8-tridecafluoro-3,7-bis(trifluoromethyl)octan-1-ol

C10H3F19O (499.988)


   
   

BMS 188745 Potassium Salt

BMS 188745 Potassium Salt

C16H16K3O7PS (499.9266)


   

Heptadecafluorooctane-2-sulfonic acid

Heptadecafluorooctane-2-sulfonic acid

C8HF17O3S (499.9375)


   

5-(Trifluoromethyl)tetradecafluoro-1-heptanesulfonic acid

5-(Trifluoromethyl)tetradecafluoro-1-heptanesulfonic acid

C8HF17O3S (499.9375)


   

4-(Trifluoromethyl)tetradecafluoro-1-heptanesulfonic acid

4-(Trifluoromethyl)tetradecafluoro-1-heptanesulfonic acid

C8HF17O3S (499.9375)


   

3-(Trifluoromethyl)tetradecafluoro-1-heptanesulfonic acid

3-(Trifluoromethyl)tetradecafluoro-1-heptanesulfonic acid

C8HF17O3S (499.9375)


   

2-(Trifluoromethyl)tetradecafluoro-1-heptanesulfonic acid

2-(Trifluoromethyl)tetradecafluoro-1-heptanesulfonic acid

C8HF17O3S (499.9375)


   

myo-Inositol 1,4,5,6-Tetrakis(phosphate)

myo-Inositol 1,4,5,6-Tetrakis(phosphate)

C6H16O18P4 (499.9287)


   
   

1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassiuM salt

1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassiuM salt

C16H16K3O7PS (499.9266)


   

myo-Inositol 1,2,3,6-tetrakisphosphate

myo-Inositol 1,2,3,6-tetrakisphosphate

C6H16O18P4 (499.9287)


   

Inositol 1,2,5,6-tetrakis(phosphate)

Inositol 1,2,5,6-tetrakis(phosphate)

C6H16O18P4 (499.9287)


   

myo-Inositol 1,2,3,4-tetrakisphosphate

myo-Inositol 1,2,3,4-tetrakisphosphate

C6H16O18P4 (499.9287)


   

2-tert-butyl-4-(2-chloro-4-methylsulfonylbenzoyl)-5-(2,4-dichlorophenyl)-1H-pyrazol-3-one

2-tert-butyl-4-(2-chloro-4-methylsulfonylbenzoyl)-5-(2,4-dichlorophenyl)-1H-pyrazol-3-one

C21H19Cl3N2O4S (500.0131)


   

N-(5,7-dibromo-2-oxo-3-indolyl)-2-ethyl-4-quinolinecarbohydrazide

N-(5,7-dibromo-2-oxo-3-indolyl)-2-ethyl-4-quinolinecarbohydrazide

C20H14Br2N4O2 (499.9483)


   

Inositol 1,3,4,5-tetrakisphosphate

Inositol 1,3,4,5-tetrakisphosphate

C6H16O18P4 (499.9287)


   

1D-myo-Inositol 3,4,5,6-tetrakisphosphate

1D-myo-Inositol 3,4,5,6-tetrakisphosphate

C6H16O18P4 (499.9287)


A myo-inositol tetrakisphosphate having the four phosphate groups placed at the 3-, 4-, 5- and 6-positions.

   

Myo-inositol 1,3,4,6-tetrakisphosphate

Myo-inositol 1,3,4,6-tetrakisphosphate

C6H16O18P4 (499.9287)


A myo-inositol tetrakisphosphate having the phosphate groups placed at the 1-, 3-, 4- and 6-positions.

   

Inositol 1,4,5,6-tetrakisphosphate

1D-myo-Inositol 1,4,5,6-tetrakisphosphate

C6H16O18P4 (499.9287)


A myo-inositol tetrakisphosphate having the four phosphate groups at the 1-, 4-, 5- and 6-positions.

   

1D-myo-Inositol 1,3,4,5-tetrakisphosphate

1D-myo-Inositol 1,3,4,5-tetrakisphosphate

C6H16O18P4 (499.9287)


A myo-inositol tetrakisphosphate having the four phosphates placed in the 1-, 3-, 4- and 5-positions.

   

1D-myo-inositol 1,2,5,6-tetrakisphosphate

1D-myo-inositol 1,2,5,6-tetrakisphosphate

C6H16O18P4 (499.9287)


A myo-inositol tetrakisphosphate having the four phosphates placed in the 1-, 2-, 5- and 6-positions.

   

[(1s,2s,3r,4s,5s,6s)-2,6-dihydroxy-3,4,5-tris(phosphonooxy)cyclohexyl]oxyphosphonic acid

[(1s,2s,3r,4s,5s,6s)-2,6-dihydroxy-3,4,5-tris(phosphonooxy)cyclohexyl]oxyphosphonic acid

C6H16O18P4 (499.9287)


   

[(1r,2r,3r,4s,5r,6r)-2,3-dihydroxy-4,5,6-tris(phosphonooxy)cyclohexyl]oxyphosphonic acid

[(1r,2r,3r,4s,5r,6r)-2,3-dihydroxy-4,5,6-tris(phosphonooxy)cyclohexyl]oxyphosphonic acid

C6H16O18P4 (499.9287)


   

[(1s,2r,3s,4s,5r,6r)-2,3-dihydroxy-4,5,6-tris(phosphonooxy)cyclohexyl]oxyphosphonic acid

[(1s,2r,3s,4s,5r,6r)-2,3-dihydroxy-4,5,6-tris(phosphonooxy)cyclohexyl]oxyphosphonic acid

C6H16O18P4 (499.9287)


   

[(1s,2r,3r,4s,5r,6s)-3,4-dihydroxy-2,5,6-tris(phosphonooxy)cyclohexyl]oxyphosphonic acid

[(1s,2r,3r,4s,5r,6s)-3,4-dihydroxy-2,5,6-tris(phosphonooxy)cyclohexyl]oxyphosphonic acid

C6H16O18P4 (499.9287)